Bridging Update in KOREA In-Jin Jang, MD Seoul National University College of Medicine and Hospital.

Slides:

Advertisements

Similar presentations

Bridging Studies Global Development W. Joe Shih Biostatistics Dept UMDNJ-School of Public Health Sept. 29, 2006 FDA/Industry Conference, Washington D.C.

Advertisements

Implementation of Bridging Study-Taiwans Experience Meir-Chyun Tzou, Ph.D. Senior Officer, and Director of Section III, Bureau of Pharmaceutical Affairs.

Robert T. O’Neill, Ph.D. Director, Office of Biostatistics CDER, FDA

Post Research Benefits Mandika Wijeyaratne MS, MD, FRCS Dept. of Surgery, Colombo.

1 WORKSHOP 4: KEY COMMENTS FROM THE PANEL DISCUSSION The 3rd Kitasato University - Harvard School of Public Health Symposium Wednesday October 2nd - Thursday.

Regulatory Clinical Trials Clinical Trials. Clinical Trials Definition: research studies to find ways to improve health Definition: research studies to.

Use of Foreign Data for Approval Ann Farrell, MD Division of Oncology Drug Products Center for Drug Evaluation and Research Food and Drug Administration.

Dr. M. Iwasaki 1 Asian Multinational Clinical Trials - Current Status & Future Direction - Dr.Masaru IWASAKI PR Japan Operations Center Aventis Pharma,

The ICH E5 Guidance: An Update on Experiences with its Implementation The ICH E5 Guidance: An Update on Experiences with its Implementation Robert T. O’Neill,

In-Jin Jang M.D., Ph.D. Clinical Pharmacology Unit, Clinical Trial Center Seoul National University Hospital (SNUH) & Seoul National University College.

K. Shimatani/ K-H Symposium/ October 22-23, What Impact Will Globalization Have on Bridging Studies Katsuyoshi Shimatani J-Clin, Pfizer.

Revolution in Asian drug development: A Korea and Japan experience Henk de Koning Gans, MD VP, Process Management Global Development Japan Pharmacia KK,

Many Important Issues Covered Current status of ICH E5 and implementation in individual Asian countries Implementation at a regional level (EU) and practical.

ICH Harmonization Eric W. Lewis, MD GlaxoSmithKline October 3 rd, 2002 The Basis of Global Drug Development.

Some Closing Remarks. Scope of Symposium Simultaneous Worldwide Development Strategies & Pharmacogenomics: 6 Sessions –1. Overview: Drs. Yazaki; Fujiwara,

Clinical Trials — A Closer Look. The Food and Drug Administration (FDA) is the main consumer watchdog for numerous products: Drugs and biologics (prescription.

Modified Megestrol The Clinical Trials by : Carolina R. Akib

Project IMPACT IMPACT National Medical Association What African Americans Should Know About Clinical Trials You’ve Got the Power!

Harmonization - ICH Robert J. Temple, MD Deputy Center Director for Clinical Science FDA/Center for Drug Evaluation and Research SACHRP March 9, 2010.

Pain and Industry: Challenges for Drug Development and Marketing Douglas Y. Shapiro, MD, PhD Pfizer Global Research and Development, Ann Arbor, MI Symposium.

Traditional Process First in Human Single Ascending Dose Multiple Ascending Dose U.S.A. Japan Phase II Phase III NDA in Japan Phase II Phase III NDA in.

HIV Clinical Trials Janice Price, M.Ed, RN HIV Clinical Research Program Coordinator Swedish Medical Center Seattle, WA USA.

1 A Bayesian Non-Inferiority Approach to Evaluation of Bridging Studies Chin-Fu Hsiao, Jen-Pei Liu Division of Biostatistics and Bioinformatics National.

The ICH E5 Question and Answer Document Status and Content Robert T. O’Neill, Ph.D. Director, Office of Biostatistics, CDER, FDA Presented at the 4th Kitasato-Harvard.

Special Topics in IND Regulation

Large Phase 1 Studies with Expansion Cohorts: Clinical, Ethical, Regulatory and Patient Perspectives Accelerating Anticancer Agent Development and Validation.

Stefan Franzén Introduction to clinical trials.

11/11/04 Clinical Research and Development in the Pharmaceutical and Biotechnology Industry Robert Anderson, MHA, CCRA, CCRCP Director, Clinical Trials.

Drug Discovery Process

1 ACI Life Sciences Mergers & Acquisitions – March 12, 2009 ASENT INTERNATIONAL SYMPOSIUM ~ Acceptability of Foreign Data~ February 26, 2011 February 26,

CR-1 Concluding Remarks and Risk/Benefit Summary Mace L. Rothenberg, MD Professor of Medicine Vanderbilt Ingram Cancer Center.

Stages of drug development

Points for Discussion Panelists: Drs.Iwasaki, Takahashi, Wood.

Integrating Scientific Advances into Regulation: Pharmacogenomics and Pharmacogenetics Janet Woodcock, M.D. Director, Center for Drug Evaluation and Research.

Jasper Ogwal-Okeng Gulu University Research Workshop 3 rd -6 th March 08.

Activity #3 Testing Medicines: A Clinical Trial. Key Words Clinical Trial – a test performed on volunteers, typically to test medicines, before the products.

Stefan Franzén Introduction to clinical trials.

Significance of Extrapolation of Foreign Clinical Data to Asian Countries Masahiro Takeuchi Div. of Biostatistics Kitasato University Graduate School The.

When do I need an IND ? FDA Guidance for Industry – Investigation New Drug Applications (INDs) - Determining Whether Human Research Studies Can Be Conducted.

Investigational Drugs Drug Laws, Drug Approval Process.

Investigational Drugs in the hospital. + What is Investigational Drug? Investigational or experimental drugs are new drugs that have not yet been approved.

FDA Focus On Consumer Protection

CLINICAL TRIALS – PHASE III. What are phase III trials  Confirmatory phase (Therapeutic confirmatory trial)  Trials are done to obtain sufficient evidence.

Dr. Mike Ferris Clinical Data for JNDA based on Bridging Japanese Data PK/PD data Bridging trial Foreign Data PK/PD data Trial to compare with bridging.

Developing medicines for the future and why it is challenging Angela Milne.

Regulatory Affairs and Adaptive Designs Greg Enas, PhD, RAC Director, Endocrinology/Metabolism US Regulatory Affairs Eli Lilly and Company.

The New Drug Development Process (www. fda. gov/cder/handbook/develop

Current Plan for Critical Path Initiative Janet Woodcock, M.D. Acting Deputy Commissioner For Operations November 5, 2004.

Exjade® (deferasirox; ICL670) NDA

GMP- A Regulatory Perspective. Regulatory Perspective in entering Global Pharma Markets.

What Does it Really Cost to Develop a New Treatment?

Drug Development and IND Process GC 690 Walter Kraft, MD.

Korea Food & Drug Administration Deputy director Kwang-Soo Joo Korea FDA Sep. 29, 2000 : Korean Good Clinical Practice & Relative Guidelines How to Manage.

Phases of Therapeutic Development by Virinder Nohria, MD, PhD Presented at ASENT Annual Meeting Symposium on Neurotherapeutics Arlington, VA March 6, 2008.

FDA Draft Guidance on the Form FDA and Other Updates David A. Lepay, M.D., Ph.D. Senior Advisor for Clinical Science, U.S. FDA DIA GCP All-SIAC.

RA/IPR Committee KRPIA GM Meeting Seoul Club Mar 30, 2011.

The Globalization of Clinical Development Technology - Current Status & NTRM - Sang - Goo Shin, MD. PhD SNU. Coll. Med. February 26, 2003.

Study Development and Design Suzanne Adams RN MPH Director, Clinical Operations Jefferson Clinical Research Institute.

Drug Development Process Stages involved in Regulating Drugs

Success Stories of Globalization in Korean Pharma

Recent Evolution of New Drug Review and Approval System in Korea

You’ve Got the Power! What African Americans Should Know About Clinical Trials National Medical Association.

ICH E17 General Principles for Planning and Design of MRCTs

Clinical Trials — A Closer Look

Clinical Drug Development

Speeding access to therapies

Type and impact of HTA-related scientific advice given during development The variability in HTA organisations and methodologies that are utilised in HTA.

Cindy Murray NP Princess Margaret Cancer Centre

Opening an IND: Investigator Perspective

A Real World Application of the Scientific Method

Presentation transcript:

Bridging Update in KOREA In-Jin Jang, MD Seoul National University College of Medicine and Hospital

Bridging Concept and Regulatory Changes in Korea

Major regulatory changes Adoption of the Bridging Concept : effective since June 2001 Separation of IND from NDA : Participation in international study enabled since December 2002 since 1999

Bridging Concept “Bridging Data” = “Korean Data” “Bridging Study” = “A trial conducted in Korean” “Bridging Data” means data on the results of trials conducted in Koreans living home and abroad, which are excerpted or selected from the clinical data package or obtained from the bridging study. “Bridging Study” means a trial conducted in Koreans in Korea for the purpose of obtaining bridging data in case it is difficult to apply the foreign clinical data as it is because there is a difference in an ethnic factor relating to the safety and efficacy of a drug.

New Product Approval New Product Candidate 7 waiver categories At least ONE Bridging Study in KOREAN (Global or Local) At least ONE Bridging Study in KOREAN (Global or Local) Bridging Exemption

Bridging Waiver Category Orphan drugs Drugs for life-threatening diseases Diagnostic reagents No systemic effect Proven ethnic insensitivity New drugs being developed inside or outside of Korea that are intended to conduct clinical trials in Korea Other drugs given waiver by KFDA

Status of Bridging Waiver (2000- Sep.2003) Waiver CategoryProduct Name (Company) No ethnic difference Antibiotic / Antiviral / Antithrombotic Zyvox (Pharmacia) Tamiflu (Roche) Arixtra (Sanofi-Synthelabo) Invanz (MSD) AIDS, Cancer, or Life-threatening disease Asperogilosis / Cancer / HIV Cancidas (MSD) Vfend (Pfizer) TS1 (Che-il, Taiho) Iresa (AstraGeneca) Crixivan (MSD)

Status of Bridging Waiver (2000-Sep.2003) -continued CategoryProduct Name (Company) Orphan DrugsZometa (Novartis) Visudyne (Novartis) Agrylin (Yu-han) Diagnostic Reagents, Radio-phacmaceuticals Optimac (I-yeon) Teseos (Sang-jung) No systemic effect Dermal cream etc. Vaniqa (BMS), Olcenon (Yu-han), Renagel (Che-il), Tazorac (Dae- woong), Herepair (Bo-ryung), Elidel (Novartis), Travatan (Alcon), Seoptanest (Sin-won)

Bridging Experience

KFDA database Increased Number of Clinical Trials

KFDA database Increased Number of Multinational Clinical Trials (Dec ~ Sep. 2003) Approved drugs for label change;  29 protocol, 21 drugs  28 Phase III & 1 Phase II studies Unapproved new drugs;  Potential bridging data generation  39 protocols, 20 compounds  22 Phase III, 6 Phase II & 1 Phase I studies

Reduced KFDA Review Time days year KFDA database

Recent Bridging Studies (Sep ~ Jul. 2003) Nine products (10 protocols) got IND’s for bridging studies Phase III; 6 protocols  Antibiotic, Antiepileptic, Antirheumatic (Biological), Osteoporosis Rx., Lipid lowering drug, Anticoagulant Phase I; 4 protocols  Antihistamine, CV biological drug, Lipid lowering drug, Antibiotic Seven protocols from domestic sponsors for product licensing-in from Japan and Italy (1)

CompanyProductActive Ingredient Indication GlaxowelcomeAvandiaRosiglitazone maleate Oral hypoglycemic agent (Diabetes ) GlaxowelcomeLotronexAlosetron HCLIrritable bowel syndrome LillyActosPioglitazoneOral hypoglycemic agent (Diabetes ) BayerLevitraVardenafilPDE5 inhibitor NovartisZelmacTegaserodIrritable bowel syndrome Approved products by PK bridging * Ten more drugs are under PK bridging study - Five in review or reporting process - Five in study or protocol development process

Bridging Issues in Korea Acceptability of Asian Data  Asian; Same ethnicity ?  Mutual recognition of Asian data ? Statistics  Statistically meaningful sample size ?  Multinational study; subgroup analysis ? Many study design issues  Similarity ? What metric?  Titration drug  Placebo Need more scientific and flexible design & review  Bayesian, Mixed effect modeling, Simulation, Pharmacogenomics, etc.